{"id":1760,"date":"2018-10-26T19:51:10","date_gmt":"2018-10-26T19:51:10","guid":{"rendered":"http:\/\/depts.washington.edu\/tlcart\/?page_id=1760"},"modified":"2023-06-02T10:08:48","modified_gmt":"2023-06-02T17:08:48","slug":"dcnpa-platform-validation","status":"publish","type":"page","link":"https:\/\/depts.washington.edu\/tlcart\/news\/about\/dcnpa-platform-validation\/","title":{"rendered":"TLC-ART&#8217;s DcNP<sup> a<\/sup> Platform Validation"},"content":{"rendered":"<p>TLC-ART&#8217;s innovative technology has now been validated to enable to produce long-acting, targeting multiple drugs simultaneously to HIV-host cells, &amp; to allow a single-dose to carry 3-4 drugs. The following boxes demonstrate platform capabilities and validation.<\/p>\n<div class=\"box-outer\">\n<div class=\"box two box-none\">\n<div class=\"tile\">\n<p> <strong>3-Drug Combo<sup> b<\/sup>: LPV\/RTV\/TFV<\/strong><\/p>\n<ul>\n<li>3 drugs in 1 nano-dosage<\/li>\n<li>One SQ dose last for 2+ wk<\/li>\n<li>HIV host cells &gt; plasma drugs<\/li>\n<li>Lymph cells &gt; PBMC<sup><strong> c<\/strong><\/sup><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29678735\">Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.<\/a><\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29432823\">Mechanism-based pharmacokinetic (MBPK) models describe three antiretrovirals delivered a long-acting anti-HIV drug combination nanoparticle formulation.<\/a><\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28099191\">Long-acting combination anti-HIV drug suspension enhances &amp; sustains higher drug levels in lymph node cells than in blood cells and plasma.<\/a><\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25402233\">Anti-HIV drug-combination nanoparticles enhance plasma exposure as well as triple-drug combination levels in cells within lymph nodes &amp; blood<\/a>. <\/p>\n<\/div>\n<div class=\"tile\">\n<p> <strong>4-Drug Combo<sup> b<\/sup>:  LPV\/RTV\/3TC\/TFV<\/strong><\/p>\n<ul>\n<li>4 drugs in 1 nano-dosage<\/li>\n<li>One SQ dose last for 2+ wk<\/li>\n<li>HIV host cells &gt; plasma drugs<\/li>\n<li>Lymph cells &gt; PBMC<sup><strong> c<\/strong><\/sup><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28099191\">Long-acting combination anti-HIV drug enhances &amp; sustains higher drug levels in lymph nodes than in blood cells &amp; plasma.<\/a><\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29548975\">Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Injection.<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"box-outer\">\n<div class=\"box two box-none\">\n<div class=\"tile\">\n<p> <strong>3-Drug Combo<sup> b<\/sup>:  ATV\/RTV\/TFV<\/strong><\/p>\n<ul>\n<li>3 drugs in 1 nano-dosage<\/li>\n<li>One SQ dose last for 2+ wk<\/li>\n<li>HIV host cells &gt; plasma drugs<\/li>\n<li>Lymph cells &gt; PBMC<sup><strong> c<\/strong><\/sup><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30121315\">Three HIV Drugs Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.<\/a> <\/p>\n<\/div>\n<div class=\"tile\">\n<p> <strong>3-Drug Combo<sup> b<\/sup>: LPV\/EFV\/TFV<\/strong><\/p>\n<ul>\n<li>3 drugs in 1 nano-dosage<\/li>\n<li>One SQ dose last for 2+ wk<\/li>\n<li>HIV host cells &gt; plasma drugs<\/li>\n<li>Lymph cells &gt; PBMC<sup><strong> c<\/strong><\/sup><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30102655\">Extended cell and plasma drug levels after one dose of a 3-in-1 nanosuspension containing lopinavir, efavirenz, and tenofovir in non-human primates.<\/a> <\/p>\n<\/div>\n<\/div>\n<\/div>\n<p><sub>a, DcNP; <strong>D<\/strong>rug <strong>c<\/strong>ombination <strong>N<\/strong>ano-<strong>P<\/strong>article platform developed by the TLC-ART Program<\/sub><\/p>\n<p><sub>b, LPV, Lopinavir; RTV, Ritonavir; 3TC, Lamivudine; EFV, Efavirenz; TFV, Tenofovir<\/sub><\/p>\n<p><sub>c, PBMC found in the blood that can be HIV infected<\/sub><\/p>\n<p><a class=\"uw-btn\" href=\"https:\/\/depts.washington.edu\/tlcart\">Home<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TLC-ART&#8217;s innovative technology has now been validated to enable to produce long-acting, targeting multiple drugs simultaneously to HIV-host cells, &amp; to allow a single-dose to carry 3-4 drugs. The following boxes demonstrate platform capabilities and validation. a, DcNP; Drug combination Nano-Particle platform developed by the TLC-ART Program b, LPV, Lopinavir; RTV, Ritonavir; 3TC, Lamivudine; EFV, Efavirenz; TFV, Tenofovir c, PBMC found in the blood that can be HIV infected Home<\/p>\n<div><a class=\"more-link\" href=\"https:\/\/depts.washington.edu\/tlcart\/news\/about\/dcnpa-platform-validation\/\">Continue reading <span class=\"screen-reader-text\">TLC-ART&#8217;s DcNP<sup> a<\/sup> Platform Validation<\/span><\/a><\/div>\n","protected":false},"author":1,"featured_media":0,"parent":8,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1760","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/pages\/1760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/comments?post=1760"}],"version-history":[{"count":45,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/pages\/1760\/revisions"}],"predecessor-version":[{"id":2854,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/pages\/1760\/revisions\/2854"}],"up":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/pages\/8"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/media?parent=1760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}